Drugs / ONAMETOSTAT
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06788509 | Dec 2024 → Jan 2028 expected | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, castration-resistant prostate carcinoma, myelodysplastic syndrome | Janssen Research & Development, LLC | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT03573310 | Jul 2018 → Sep 2025 | cancer, myelodysplastic syndrome, non-Hodgkin lymphoma | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONAMETOSTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL4249337 ↗ |
| Known as | JNJ-64619178 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06788509 ↗ |
| Action | Inhibit | “an Inhibitor of PRMT5” NCT03573310 ↗ |
| Modality | Small molecule | — CHEMBL4249337 ↗ |
| Route | Oral | “JNJ-64619178 capsules to be administered orally.” NCT03573310 ↗ |
| Target | PRMT5 | “Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5)” NCT03573310 ↗ |